Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ranbaxy offers all strengths of Sumatriptan tablets

Ranbaxy offers all strengths of Sumatriptan tablets

14th August 2009

Ranbaxy has received approval from the Food and Drug Administration to manufacture Sumatriptan Succinate tablets in doses of 25 mg and 50 mg.

The regulator, in conjunction with Office of Generic Drugs, has concluded that the tablets, which are used to treat adult migraine attacks with or without aura, have the same therapeutic effect as GlaxoSmithKline’s listed drug Imitrex.

“This product will be launched immediately to all classes of trade and further expands our product portfolio of affordable generic product formulations that will be of benefit to patients [and] healthcare professionals,” stated Bill Winter, vice-president of trade sales for North America at Ranbaxy.

At the end of June this year, total annual market sales of Sumatriptan Succinate 25 mg and 50 mg tablets stood at $379 million (228.5 million pounds).

Earlier this year, Ranbaxy announced that it had initiated trials on the lead compound for respiratory inflammation and was awaiting its successful completion.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.